Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab + talquetamab for functional high-risk relapsed/refractory multiple myeloma
ACTRN12625000438459Phase 2Recruiting
- Sponsor
- Australasian Myeloma Research Consortium
- Start
- Jun 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teclistamab and talquetamab in multiple myeloma (MM), sponsored by Australasian Myeloma Research Consortium. Primary endpoint: Partial response or better within first four cycles. Started Jun 2025; status: recruiting.
02
Drugs
teclistamabtalquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12625000438459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000438459.